Enzyme conjugate

•Download as PPT, PDF•

0 likes•285 views

Creative Biolabs

In enzyme conjugate, TGs can be used to conjugate small molecules onto antibodies Gln residues, for instance Q295 on IgG, to form ADCs with a potential DAR of 2. The removal or size reduction of N297 glycans is prerequisite to reduce spacial hindrance for TG activity. Alternatively, a mutation that converts N297 to Q also facilitates the TG-mediated conjugation and results in ADCs with a potential DAR of up to 4. https://www.creative-biolabs.com/adc/enzyme-mediated-modification-and-conjugation.htm

Health & Medicine

中文字体：微雅黑软
英文字体： Calibri
片可除后一替图删键换
幻灯片色可在主置内一更改颜题设键

08/01/19

08/01/19

08/01/19

08/01/19

08/01/19

08/01/19

08/01/19

08/01/19

08/01/19
中文字体：微雅黑软
英文字体： Calibri
片可除后一替图删键换
幻灯片色可在主置内一更改颜题设键

More Related Content

More from Creative Biolabs

Numerous viruses are being developed pre-clinically and clinically. An investigation of all registered clinical trials in 2017 demonstrates 78 interventional trials regarding OVs. This ability for near-universal therapeutic impact in cancer makes OVs a popular therapeutic tool. Today, both preclinical and early-stage clinical trials are intensively investigating the approach to improve oncolytic virotherapy. https://www.creative-biolabs.com/oncolytic-virus/applications-of-oncolytic-viruses-in-cancer-treatment.htm

Oncolytic Virus Application

Oncolytic Virus Application

Oncolytic Virus Application

Creative Biolabs

Oncolytic Virus Animal Model

Oncolytic Virus Animal Model

Oncolytic Virus Animal Model

Creative Biolabs

Abciximab mechanism of action

Abciximab mechanism of action

Abciximab mechanism of action

Creative Biolabs

Abagovomab mechanism of action

Abagovomab mechanism of action

Abagovomab mechanism of action

Creative Biolabs

Wnt Pathway

Creative Biolabs

TNF works through two receptors, TNFR1 and TNFR2. TNFR1 is the major signal receptor of TNF-α. TNFR2, which mediates limited biological responses, binds to TNF-α and TNF-β. TNF signaling transduction through TNFR1 and TNFR2 can induce a variety of cellular responses, which depends on many factors, including the metabolic state of the cell and the adaptor proteins present in the cell.https://www.creativebiolabs.net/tnf-signaling-pathway.htm

TNF Pathway

Creative Biolabs

TLR Pathway

Creative Biolabs

TGF-β Pathway

Creative Biolabs

TCR Pathway

Creative Biolabs

RAS Pathway

Creative Biolabs

PPAR Pathway

Creative Biolabs

VPI3K-AKT Pathway

VPI3K-AKT Pathway

VPI3K-AKT Pathway

Creative Biolabs

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Creative Biolabs

Anti-CAIX/CA9 Recombinant Antibody

Anti-CAIX/CA9 Recombinant Antibody

Anti-CAIX/CA9 Recombinant Antibody

Creative Biolabs

Anti-B Cell Lymphomas Recombinant Antibody

Anti-B Cell Lymphomas Recombinant Antibody

Anti-B Cell Lymphomas Recombinant Antibody

Creative Biolabs

Anti-B. anthracis anthrax protective antigen

Anti-B. anthracis anthrax protective antigen

Anti-B. anthracis anthrax protective antigen

Creative Biolabs

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Creative Biolabs

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Creative Biolabs

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Creative Biolabs

Anti-Human MMP9 Recombinant Antibody

Anti-Human MMP9 Recombinant Antibody

Anti-Human MMP9 Recombinant Antibody

Creative Biolabs

More from Creative Biolabs (20)

Oncolytic Virus Application

Oncolytic Virus Application

Oncolytic Virus Application

Oncolytic Virus Animal Model

Oncolytic Virus Animal Model

Oncolytic Virus Animal Model

Abciximab mechanism of action

Abciximab mechanism of action

Abciximab mechanism of action

Abagovomab mechanism of action

Abagovomab mechanism of action

Abagovomab mechanism of action

Wnt Pathway

TNF Pathway

TLR Pathway

TGF-β Pathway

TCR Pathway

RAS Pathway

PPAR Pathway

VPI3K-AKT Pathway

VPI3K-AKT Pathway

VPI3K-AKT Pathway

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Afuco™ Anti-CD19 ADCC Recombinant Antibody (Taplitumomab), ADCC Enhanced

Anti-CAIX/CA9 Recombinant Antibody

Anti-CAIX/CA9 Recombinant Antibody

Anti-CAIX/CA9 Recombinant Antibody

Anti-B Cell Lymphomas Recombinant Antibody

Anti-B Cell Lymphomas Recombinant Antibody

Anti-B Cell Lymphomas Recombinant Antibody

Anti-B. anthracis anthrax protective antigen

Anti-B. anthracis anthrax protective antigen

Anti-B. anthracis anthrax protective antigen

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Anti-B. Anthracis Anthrax Protective Antigen (Raxibacumab)

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Afuco™ Anti-AFP ADCC Recombinant Antibody (Tacatuzumab), ADCC Enhanced

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Afuco™ Anti-CD22 ADCC Recombinant Antibody (Inotuzumab), ADCC Enhanced

Anti-Human MMP9 Recombinant Antibody

Anti-Human MMP9 Recombinant Antibody

Anti-Human MMP9 Recombinant Antibody

Recently uploaded

June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels: - ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING - WOMEN’S HEALTH: FERTILITY PRESERVATION - WHAT’S NEW IN THE TREATMENT OF INFECTIOUS, ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES? - ARTIFICIAL INTELLIGENCE AND ETHICS - GENE THERAPY - BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE - ETHICAL CHALLENGES IN LIFE SCIENCES - Prix Galien International Awards Ceremony

Prix Galien International 2024 Forum Program

Prix Galien International 2024 Forum Program

Prix Galien International 2024 Forum Program

Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram. Learning objectives: 1. Define an electrocardiogram (ECG) and electrocardiography 2. Describe how dipoles generated by the heart produce the waveforms of the ECG 3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II) 4. Differentiate between intervals and segments 5. Enlist some common indications for obtaining an ECG Study Resources: 1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition 2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition 3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition 4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/ 5. ECG in Medical Practice by ABM Abdullah, 4th edition 6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics

The Normal Electrocardiogram - Part I of II

The Normal Electrocardiogram - Part I of II

The Normal Electrocardiogram - Part I of II

MedicoseAcademics

RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0). CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Fundamental of Radiobiology -SABBU.pptx

Fundamental of Radiobiology -SABBU.pptx

Fundamental of Radiobiology -SABBU.pptx

Compare home pulse pressure components collected directly from home

Compare home pulse pressure components collected directly from home

Compare home pulse pressure components collected directly from home

Gauri Gawande(9) Constipation Final.pptx

Gauri Gawande(9) Constipation Final.pptx

Gauri Gawande(9) Constipation Final.pptx

Ocular injury ppt Upendra pal optometrist upums saifai etawah

Ocular injury ppt Upendra pal optometrist upums saifai etawah

Ocular injury ppt Upendra pal optometrist upums saifai etawah

i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource. This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and Associate Division Director for Ambulatory Operations The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma. STATEMENT OF NEED Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL. Target Audience Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL). Learning Objectives 1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL 2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults 3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol that is rapidly distributed in the body and brain. Ethanol alters many neurochemical systems and has rewarding and addictive properties. It is the oldest recreational drug and likely contributes to more morbidity, mortality, and public health costs than all illicit drugs combined. The 5th edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) integrates alcohol abuse and alcohol dependence into a single disorder called alcohol use disorder (AUD), with mild, moderate, and severe subclassifications (American Psychiatric Association, 2013). In the DSM-5, all types of substance abuse and dependence have been combined into a single substance use disorder (SUD) on a continuum from mild to severe. A diagnosis of AUD requires that at least two of the 11 DSM-5 behaviors be present within a 12-month period (mild AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria). The four main behavioral effects of AUD are impaired control over drinking, negative social consequences, risky use, and altered physiological effects (tolerance, withdrawal). This chapter presents an overview of the prevalence and harmful consequences of AUD in the U.S., the systemic nature of the disease, neurocircuitry and stages of AUD, comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and pharmacotherapies for AUD.

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Dr Jeenal Mistry

Contact us if you are interested: Email / Skype : kefaya1771@gmail.com Threema: PXHY5PDH New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH ! Contact me on Threema or skype to start big business!! Hot-sale products: NEW HOT EUTYLONE WHITE CRYSTAL!! 5cl-adba precursor (semi finished ) 5cl-adba raw materials ADBB precursor (semi finished ) ADBB raw materials APVP powder 5fadb/4f-adb Jwh018 / Jwh210 Eutylone crystal Protonitazene (hydrochloride) CAS: 119276-01-6 Flubrotizolam CAS: 57801-95-3 Metonitazene CAS: 14680-51-4 Payment terms: Western Union,MoneyGram,Bitcoin or USDT. Deliver Time: Usually 7-15days Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet. Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details. We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

The History of Diagnostic Medical imaging

The History of Diagnostic Medical imaging

The History of Diagnostic Medical imaging

How to Give Better Lectures: Some Tips for Doctors

How to Give Better Lectures: Some Tips for Doctors

How to Give Better Lectures: Some Tips for Doctors

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Savita Shen $i11

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Recently uploaded (20)

Prix Galien International 2024 Forum Program

Prix Galien International 2024 Forum Program

Prix Galien International 2024 Forum Program

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

Report Back from SGO 2024: What’s the Latest in Cervical Cancer?

The Normal Electrocardiogram - Part I of II

The Normal Electrocardiogram - Part I of II

The Normal Electrocardiogram - Part I of II

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...

Fundamental of Radiobiology -SABBU.pptx

Fundamental of Radiobiology -SABBU.pptx

Fundamental of Radiobiology -SABBU.pptx

Compare home pulse pressure components collected directly from home

Compare home pulse pressure components collected directly from home

Compare home pulse pressure components collected directly from home

Gauri Gawande(9) Constipation Final.pptx

Gauri Gawande(9) Constipation Final.pptx

Gauri Gawande(9) Constipation Final.pptx

Ocular injury ppt Upendra pal optometrist upums saifai etawah

Ocular injury ppt Upendra pal optometrist upums saifai etawah

Ocular injury ppt Upendra pal optometrist upums saifai etawah

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

1130525--家醫計畫2.0糖尿病照護研討會-社團法人高雄市醫師公會.pdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Is preeclampsia and spontaneous preterm delivery associate with vascular and ...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Arterial health throughout cancer treatment and exercise rehabilitation in wo...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

Impact of cancers therapies on the loss in cardiac function, myocardial fffic...

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

DECIPHERING COMMON ECG FINDINGS IN ED.pptx

The History of Diagnostic Medical imaging

The History of Diagnostic Medical imaging

The History of Diagnostic Medical imaging

How to Give Better Lectures: Some Tips for Doctors

How to Give Better Lectures: Some Tips for Doctors

How to Give Better Lectures: Some Tips for Doctors

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Non-Invasive assessment of arterial stiffness in advanced heart failure patie...

Enzyme conjugate

1. 中文字体：微雅黑软英文字体： Calibri 片可除后一替图删键换幻灯片色可在主置内一更改颜题设键

10. 08/01/19 中文字体：微雅黑软英文字体： Calibri 片可除后一替图删键换幻灯片色可在主置内一更改颜题设键